Antithrombogenicity evaluation of a centrifugal blood pump.
The Gyro C1E3 pump was developed not only for cardiopulmonary bypass but also as a short-term assist device. The main purpose of this study was to examine the correlation between the thrombus formation factor and the Gyro C1E3 pumps. Seven pumps were implanted into 3 calves and evaluated for different periods of duration as a paracorporeal left ventricular assist device (LVAD). One pump was subjected to percutaneous cardiopulmonary support condition (PCPS) (total pressure head 500 mm Hg with a pump flow rate of 3 L/min). The anticoagulation treatment consisted of a continuous administration of heparin to maintain an activated clotting time (ACT) of 200-250 during the LVAD study and 250-300 during the PCPS study. After the experiment, the pumps were disassembled and examined. In cases where there were any blood-derived deposits inside the pumps, the dry weight of these thrombi that adhered to the bearing area of the pump was measured. A multiple correlation was attempted to speculate possible thrombus formation. The estimated dry weight of thrombi was calculated from pump flow rate, pumping day, motor speed, and activated clotting time. This equation was estimated dry weight of thrombi = 1.140 x pump flow rate -0.001 motor speed + 1.652 pumping time -0.041 x ACT + 2.198 R2 = 0.944. This study suggested that there was a possibility to calculate the amount of adhered thrombus formation from pump flow rate, motor speed, pumping day, and ACT.
Nakata
K
K
Department of Surgery, Baylor College of Medicine, Houston, Texas, USA.
Yoshikawa
M
M
Takano
T
T
Maeda
T
T
Nonaka
K
K
Linneweber
J
J
Kawahito
S
S
Glueck
J
J
Fujisawa
A
A
Makinouchi
K
K
Yokokawa
M
M
Nosé
Y
Y
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage; D002417:Cattle; D002498:Centrifugation; D006353:Heart-Assist Devices; D006493:Heparin / Q000008:administration & dosage; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D006493:Heparin